Phillips 66 (PSX) reported revenues of $29.7 billion for the second quarter of 2018, up 23% from the same period last year. Net earnings totaled $1.33 billion or $2.84 per diluted share compared to $524 million or $1.07 per diluted share in the prior-year period. Adjusted EPS was $1.32 billion or $2.80 per share.
Revenue and adjusted EPS numbers beat analyst expectations. Net earnings benefitted from year-over-year growth in earnings at all four segments as well as a diversified portfolio.
During the quarter, Phillips 66 returned $602 million to shareholders through dividends and share repurchases. Capital expenditures and investments totaled $538 million.
Greg Garland, Chairman and CEO said, “We advanced strategic growth initiatives and continued to reward our shareholders. In Refining, we operated at full capacity and continued to capture the benefits of advantaged feedstocks through our integrated supply network. CPChem achieved full operations at its new US Gulf Coast petrochemicals assets, contributing to solid earnings growth. In Midstream, the expansion of our Sweeny Hub will further grow and optimize our NGL value chain. Most recently, Phillips 66 Partners completed the Gray Oak Pipeline open season to capitalize on growing Permian crude production.”
Crude unit modifications to run more domestic crudes and reduce feedstock costs have been completed at the Lake Charles Refinery, and additional improvements are expected in the fourth quarter. Completion is now expected in the third quarter of 2019.
Related: Phillips 66 Q2 2018 Earnings Call Transcript
Related: Phillips 66 Q1 2018 Earnings Infographic
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Comments
Comments are closed.